1 / 108

Plants and microbes as drug targets

Plants and microbes as drug targets . Prof. H.S. Prakash Department of Biotechnology University of Mysore Manasagangotri, Mysore 570 006 . Higher plants – a rich source of novel compounds. 400,000 higher plant species 10% characterized chemically

marlie
Télécharger la présentation

Plants and microbes as drug targets

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Plants and microbes as drug targets Prof. H.S. Prakash Department of Biotechnology University of Mysore Manasagangotri, Mysore 570 006

  2. Higher plants – a rich source of novel compounds • 400,000 higher plant species • 10% characterized chemically • One-fourth of pharmaceuticals derived from plants • 11% of the 252 basic and essential drugs (WHO) are exclusively derived from flowering plants • Plant-derived drugs have huge market value US$30 billion in USA (2002)

  3. Natural metabolites • Secondary metabolites have no recognized role in maintaining fundamental life processes but have important role in the interaction of the cells with its environment • Only half the structures elucidated • Chemically highly diverse but characteristic of a plant

  4. Role of secondary metabolites • Not clear • Important for survival of the plants in its ecosystem • Antimicrobial, anti-insect, deter potential predators • Discourage competing plant species • Attract pollinators or symbionts • Flovours, fragrances, dyes, pesticides and pharmaceuticals

  5. Major groups • Based on biosynthetic origins structurally divided into five major groups • Polyketides: Acetate-mevalonate • Isoprenoids:Terpenoids and steroids from 5-C precursor isopentenyldiphosphate (IPP) • Alkaloids: via classical mevalonate pathway or the novel MEP (non-mevalonate or Rohmer) pathway • Phenylpropanoids: having C6-C3 units from aromatic amino acids phenylalanine or tyrosine • Flavonoids: combination of phenylpropanoids and polyketides

  6. Biosynthetic pathways • Often long, complex multi-step events catalyzed by various enzymes and still largely unknown • Alkaloid biosynthesis: Best studied, 12,000 structures are known • Production of specific alkaloid: Often restricted to certain plant families • Flavonoids are abundant in many plant species

  7. Examples – Natural drugs • Vinblastine, vincristine: Madagaskar periwinkle – Catharanthus roseus • Anticancer – Paclitaxel (Taxol), podophyllotoxin, camptothecin • Analgesic – Morphine • Semi-synthetic drugs – steroidal hormones derived from diosgenin – Dioscorea; corticosteroids, contraceptives, sex hormones

  8. Plant chemical diversity • Much greater than any chemical library • Enormous reservoir • ‘Omics’-based – functional genomics – screening • Limited success of combinatorial chemistry or computational drug design

  9. Combinatorial chemistry • Designed organic chemistry enables optimization of molecular structures – Not attractive • 1981-2002: 28% (351) of 1031 new drug entities (NDEs) either natural products or derivatives • 24% synthesized based on natural resources • Major group: Anti-microbial (66%), Anti-cancer (52%), Anti-hypertensive, Anti-inflammatory

  10. Plant cell culture – an alternative production system • Plants are difficult to cultivate or becoming endangered • Chemical synthesis – complex structure/specific stereochemical requirements • Cell or organ culture: attractive alternative • But limited commercial success because of empirical nature of selecting high-yielding, stable cultures and lack of biosynthetic pathway and its regulation

  11. Cell cultures • Production limitation • Treatment of undifferentiated cells with elicitors such as methyljasmonate, salicylic acid, chitosan and heavy metals • Organ culture: Hairy root (alkaloids) or shooty teratoma (tumor-like) cultures monoterpenes

  12. Cell suspension cultures • Shikonin from Lithospermumerythrorhizon • Berberine from Coptis japonica • Rosmarinin acid from Coleus blumeii • Sanguinarine from Papaversomniferum • Paclitaxel from Taxusbrevifolia • Bottlenecks – low productivity, process technological issues (Bioreactor design, cultivation conditions) • Functional genomics – Newer opportunities

  13. Metabolic engineering strategies • Decrease the catabolism of the desired compound • Enhance the expression or activity of a rate-limiting enzyme • Prevent feedback inhibition of a key enzyme • Enhance expression or activity of all genes involved in the pathway • Compartmentalization of the desired compound • Conversion of an existing product into a new product

  14. Metabolic engineering strategies • Gain-of-function and loss-of-function of genes • Discovery of transcription factors that regulate the entire pathway • Overexpression of transporters • Eg. Overexpression of rate-limiting upstream enzyme putrescine N-methyltransferase (PMT) and the downstream enzyme hyoscyamine 6β-hydroxylase (H6H) of tropane alkaloid biosynthesis enhanced production of scopolamine in cultivated hairy roots

  15. Transcriptional regulation • Part of terpenoidindole alkaloid biosynthesis in Catharanthusroseusis under the control of ORCA3, a jasmonate-responsive APETALA2 (AP2)-domain transcription factor • Constitutive overproduction of ORCA3 – enhanced terpenoidindole alkaloids • Maize transcription factors LC and C1 in tomato fruits upregulated the flavonoid pathway – kaempferol • ANT1 - Anthocyanin biosynthesis, glycosylation and transport in vacuoles

  16. Transporters • Nicotine and other alkaloids are exported by overexpressed yeast ABC transporter PDR5 in transgenic tobacco thus decreasing cellular toxicity • Multidrug resistance protein cjMDR1 obtained from berberine-producing Coptis japonica cells functions as an ABC transporter – probably pumps berberine into xylem cells for root-to-rhizome translocation

  17. Functional genomics and secondary metabolites • Transcriptomics, proteomics, metabolomics • Genomics tools for medicinal plants are limited • Tools: 2-D gel electrophoresis-based proteomics, transcript analysis tools such as differential display, EST databases, micro-arrays

  18. Possible functional genomics approach • High-throughput selection and testing of genes • Could be used without pre-existing sequence knowledge • Profiling methods (e.g. micro-arrays) require genomic information, hence cannot be used

  19. Functional genomic approach • Elicit the metabolites (e.g. methyl jasmonate) • Use Genome-wide transcript profiling methods to identify expressed genes • Combining cDNA-amplified fragment length polymorphism, transcript profiling and targeted metabolic profiling in a time course experiment following elicitation, 591 genes out of 20,000 visualized genes were identified

  20. Functional genomic approach • Homology searches: 58% genes had known function • Include Nicotine biosynthesis genes ornithine decarboxylase (ODC), arginine decarboxylase (ADC), quinolinate acid phosphoribosyl transferase (QPT) and many novel genes – alkaloid biosynthesis • Also putative proteins of unknown function (15%), signal transduction proteins such as receptors, kinases, phosphatases and transcription factors

  21. High-throughput functional analysis • Isolation of full-length cDNAs. • High-throughput construction of expression vectors • Developing a rapid transformation system • Downscaling the plant cell cultures • Rapid targeted metabolite profiling • Quantitative analysis of desired compounds

  22. Problems in characterizing plant metabolome • Highly complex nature and chemical diversity • Range of chemical properties • Far more complex than metabolite profiling of primary metabolites

  23. New lead molecules through combinatorial biochemistry • Major classes of secondary metabolites (Polyketides, isoprenoids, alkaloids, phenylproponoids and flavonoids) subdivided into several subclasses • Eg. 12,000 known alkaloids subdivided into 15 subclasses: proto-, piperdine-, pyrrolidine-, pyridine-, quinolizidine-, trophane-, pyrrolizidine-, imidazole-, purine-, quinoline-, isoquinoline-, quinazoline-, indole-, terpenoid- and steroidal-alkaloids

  24. Combinatorial biochemistry • Secondary metabolites belonging to the same subclass are not always synthesized from the same primary metabolites but their chemical structures share the same basic skeleton • Because of activity of enzymes with different substrate- and stereo-specificity, the chemical diversity and biological activity of the molecules belonging to the same subclass can be enormous • Some subclasses are found only in a few plant familites (e.g. tropane alkaloids found in only Solanaceae and Erythroxylaceae), whereas flavonoids are widely distributed

  25. Combinatorial biochemistry • Different plants synthesize structurally similar but nevertheless diverse molecules • An enzyme isolated from one plant might encounter new but related substrates when introduced into another plant • Hybrid – new secondary metabolites • Somatic hybrids – Solanumbrevidensx S.tuberosum, both produce glycoalkaloid precursor teinemine – converted by a hydrogenase to tomatidine in S. brevidens and solanidineglycoalkaloid in S. tuberosum • Hybrid produced tomatidine and solanidine, also novel glycoalkaloid called demissidine

  26. Yeast cell factories • Biocatalysts – biotransformation – organic synthesis • Major synthetic technologies based on biocatalytic reactions • Fermentation: A biological method resulting in products which are the result of the complex metabolism of microorganisms starting with inexpensive simple C and N sources • Enzymation (microbial transformation, microbial conversion, biotransformation, bioconversion): Living cells not necessary but only act as ‘simple bag of enzymes or catalysts’ – one or few-step

  27. Alternative yeast Candida, Cryptococcus, Geotrichum, Issatchenkia, Kloeckera, Kluyveromyces, Pichia (including Hansenula polymorpha = P. angusta), Rhodotorula, Rhodosporidium, Schizosaccharomyces pombe, Torulopsis, Trichosporon, Trigonopsis variabilis, Yarrowia lipolytica and Zygosaccharomyces rouxii

  28. Generation of designed microorganisms • Increasing number of sequenced genes and whole genomes • New bioinformatic tools for analyzing the wealth of information • Biochemically well-characterized biosynthetic pathways • Well established genetic engineering techniques

  29. Designed microorganisms(Genetic engineering approaches) • Construction of synthetic pathways for the production of structurally complex, natural products like isoprenoids or polyketides • Delete harmful genes • E. coli, B. subtilis, Schizosaccharomyces pombe (fission yeast)

  30. Chemical reactions catalyzed by wild-type yeast whole-cell biocatalysts • Baker’s yeast (S. cerevisiae): Ideal as stereo-selective biocatalysts – chiral intermediates in the synthesis of enantiomerically pure compounds • Non-pathogenic, inexpensive, simple to grow at large scale, cells can be stored indefinitely in dried form

  31. Main enzymatic reactions performed by wild-type yeast Reduction of C=O bonds • Asymmetric reduction of carbonyl-containing compounds (E.g. Furfural to furfuryl alcohol) • Reduces simple aliphatic and aromatic ketonesresulting in (S)-alcohols • Whole-cell (redox)-biocatalysts contain necessary cofactors and metabolic pathways • Cheap C sources (glucose, saccharose) • Biocatalysts and cofactors are well protected – more stable • Substrates – non-natural – toxic (0.3% per volume) • Large amounts of biomass and by-products – impede product recovery • Transport phenomenon

  32. Wild type yeast • Different strains – different specificities • Different dehydrogenaseswith overlapping substrate specificities but opposite stereoselectivities • Variety of oxidoreductases • Improved selectivity: substrate modification, changes in cultivation conditions, application of different C-sources, use of inhibitors, two-phase systems, water immiscible ionic liquids, biocompatible solvents to provide substrate reservoir and in situ extracting agent

  33. Reduction of C=C-bonds • Flavin-depredox enzyme in yeast (Warburg and Christian, 1933) • Known as ‘old yellow enzymes’ (Flavin cofactor) • Typical substrates are alkenes ‘activated’ by electron-withdrawing substituents • Reduced at the expense of NAD(P)H leading to enantiomerically pure alkanes creating two chiral carbon centers • Excellent stereoselectivities • Cells provide both enoatereductaseand alcohol dehydrogenases, both depend on the same nicotinamide cofactor • E.g. asymmetric bioreductions of α,β-unsaturated ketones with S. cerevisiaeled to (R)-2,2,6-trimethylcyclohexane-1,4-dione used for 3-hydroxycarotenoid production

  34. Oxidation and racemization reactions • Yeast alcohol oxidases– oxidation of methanol and other primary alcohols • Instead of creating a chiral center, it is ‘destructed’, hence limited synthetic use except for regioselective oxidation of polyols • Oxidation of sulfides can result in chiralsulfoxides used in organic synthesis as asymmetric auxilliary groups to control the stereochemical outcome

  35. Hydrolase reactions • Hydrolysis reactions – proteinases, lipases, esterases • Converted 1-alkyn-3-yl acetates to corresponding alcohols and acceptable enantioselectivities

  36. Formation of C-C-bonds • Acyloin condensation forms (1R)-phenylacetylcarbinol, a chiralsynthon of D-ephedrine • Involve pyruvatedecarboxylase • Benzaldehyde subjected to acyloid condensations • Conversion of α,β-unsaturated aldehydes giving optically active diols and production of the α-14 chromanyl moiety of α-tocopherol (Vit E)

  37. Industrial application of yeast whole-cell • Combining microbiological and chemical synthesis • E.g. S. cerevisiae: Acyloin-type condensation of benzaldehyde resulting in (1R)-phenylacetylcarbinol which is subsequently converted to (1R, 2S)-ephedrine and (1R,2S)-pseudoephedrine • Candida rugosa enoyl-CoA hydratase catalyzes butyric acid to (R)-β-hydroxy-n-butyric acid • Zygosaccharomyces rouxii: enantioselective reduction of 3,4-methylenedioxy-phenylacetone to the corresponding (S)-alcohol (Eli Lilly)

  38. Industrial application of yeast whole-cell • Pichia methanolica (Bristol-Myers Squibb): Reductase for the reduction of ethyl5-oxo-hexanoate and 5-oxo-hexanenitrile to the corresponding (S)-alcohols • Phenylalanine dehydrogenase from Thermoactinomyces intermedium used to produce Chiral intermediates for the production of antihypertensive drug, Omapatrilat

  39. Recombinant yeasts • Designer yeasts for biocatalytic applications • Metabolic engineering for heterologous protein production, extension of substrate range, pathways leading to new products, pathways for the degeneration of xenobiotics, engineering of cellular physiology for process improvement, elimination/reduction of by-product formation and improvement of yield or productivity • Production of high value chemicals – ethanol, glycerol, xylitol, succinic acid and other organic acids

  40. Engineered yeast platform • Mostly for chiral precursors for the pharmaceutical, food or feed industry including single- and multi-step biocatalytic reactions • Pathway engineering leading to structurally complex natural products

  41. Organic single or few-step transformations • Optically pure ethyl (R)4-chloro-3-hydroxybutanoate from prochiral β-keto ester • Altered oxidoreductases – combining gene deletion and overexpression • GRAS status: Improved synthesis of the food flavoring methyl benzoate by expressing the Antirrhinum majus benzoid acid methyltransferase (BAMT) under the control of Cu-inducible CUP1 promoter • By encoding β-glucosidase in yeast elevated the resveratrol content • Expression of cyclohexanone monooxygenase from the Acinetobacter in S. cerevisiae – variety of substituted cycloalkanones and several sulfides, dithianes and dithiolanes

  42. Cofactor regeneration • For asymmetric reductions cofactor-dep enzymes are required • Considering the cost of NAD(P)+ and NAD(P)H, their stoichiometric application is not economically feasible • Whole-cell biocatalysts provide the cheapest cofactor regeneration system • Introduced membrane-bound transhydrogenase from E. coli

More Related